TherapeuticsMD and Spark Networks are beaten-down names with recent buying interest from insiders in common.
There are a number of issues to consider from a trading standpoint as we start the week.
The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.
Let's see how the charts are shaping up ahead of the numbers Friday.
Since GE CEO Larry Culp took the reins three years ago his plan has been nothing if not aggressive.
Knee-jerk reactions to earnings results can create attractive opportunities.
Here's what traders can do.
Let's take a look at the charts of this healthcare provider ahead of Wednesday's report.
There is resistance overhead for the stock of the health plan operator after a spurt upward, so wait to buy it on a breakout over a key price.
New technology could take out some of the pain -- and subjectivity -- for those looking to invest in this emerging line of treatments.